Venus Medtech, a Hangzhou cardiac device maker, bought a portfolio of cardiac valve technology from Transcatheter Technologies GmbH of Germany. The Transcatheter system allows the surgeon to reposition the valve once it is implanted, a unique feature. Using the technology, Venus will develop and market a third-gen valve system for use in China and the world. Venus' transcatheter aortic valve is currently awaiting CFDA approval. Terms of the agreement were not disclosed.
